Physician profile
Johnny P Adkins
NPI 1164472908
$172,163.20
in general payments reported to CMS, 2019-2025
5 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $24K · 2021: $25K · 2022: $26K · 2023: $18K · 2024: $27K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,238.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $148,262.00 | 2020-2025 | |
| Shire North American Group INC | $23,808.00 | 2019 | |
| Astellas Pharma US INC | $44.66 | 2019 | |
| Pfizer INC. | $33.26 | 2019 | |
| Novo Nordisk INC | $15.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.